Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre

Intralesional meglumine antimoniate for the treatment of localised cutaneous leishmaniasis: a retrospective review of a Brazilian referral centre

Although intralesional meglumine antimoniate (MA) infiltration is considered an option for cutaneous leishmaniasis (CL) therapy and is widely used in the Old World, there have been few studies supporting this therapeutic approach in the Americas. This study aims to describe outcomes and adverse even...

Full description

Bibliographic Details
Main Authors:	Rosiana Estéfane da Silva, Antonio Toledo Júnior, Maria Camilo Senna, Ana Rabello, Gláucia Cota
Format:	Article
Language:	English
Published:	Fundação Oswaldo Cruz (FIOCRUZ) 2016-08-01
Series:	Memorias do Instituto Oswaldo Cruz
Subjects:	cutaneous leishmaniasis therapy intralesional infiltration antimoniate meglumine
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762016000800512&lng=en&tlng=en

Similar Items

Meglumine antimoniate intralesional infiltration for localised cutaneous leishmaniasis: a single arm, open label, phase II clinical trial
by: Dario Brock Ramalho, et al.
Published: (2018-06-01)

Towards a standard protocol for antimony intralesional infiltration technique for cutaneous leishmaniasis treatment
by: Rosiana Estéfane da Silva, et al.

RESOLUTION OF CUTANEOUS LEISHMANIASIS AFTER ACUTE ECZEMA DUE TO INTRALESIONAL MEGLUMINE ANTIMONIATE
by: Erica de Camargo Ferreira e Vasconcellos, et al.
Published: (2014-07-01)

Comparison of Intralesional Meglumine Antimoniate Plus Oral Allopurinol with Intralesional Meglumine Antimoniate Alone for the Treatment of Cutaneous Leishmaniasis- A Prospective Study
by: Nida Qayyum, et al.
Published: (2024-05-01)

Treatment of cutaneous leishmaniasis with combination of allopurinol and low dose of meglumine antimoniate
by: A Momeni, et al.
Published: (2001-03-01)

Comparison of Intralesional Sodium Stibogluconate versus Intralesional Meglumine Antimoniate for the Treatment of Leishmania major Cutaneous Leishmaniasis
by: Michal Solomon, et al.
Published: (2024-04-01)

Warning against increasing cases of cutaneous leishmaniasis and unavailability of meglumine in Pakistan
by: Sadia Iram, et al.
Published: (2023-12-01)

Intralesional Meglumine Antimoniate: Safe, Feasible and Effective Therapy for Cutaneous Leishmaniasis in Bolivia
by: Ernesto Rojas Cabrera, et al.
Published: (2022-10-01)

PANCREATIC TOXICITY AS AN ADVERSE EFFECT INDUCED BY MEGLUMINE ANTIMONIATE THERAPY IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS
by: Marcelo Rosandiski LYRA, et al.

Treatment of Canine Leishmaniasis with Meglumine Antimoniate: A Clinical Study of Tolerability and Efficacy
by: Serena Digiaro, et al.
Published: (2024-08-01)

The Efficacy of Intralesional Meglumine Antimoniate (Glucantime) versus a Combination of Topical Trichloroacetic Acid 50% and Local Heat Therapy by Non-Ablative Radiofrequency on Cutaneous Leishmaniasis Lesions
by: Mohammad Ali Nilforoushzadeh, et al.
Published: (2011-12-01)

The Additive Effect of Topical Ciprofloxacin 2% on Intralesional Glucantime Injection in Treatment of Cutaneous Leishmaniasis
by: Mohamadjavad Yazdanpanah, et al.
Published: (2020-06-01)

Low dose systemic or intralesional meglumine antimoniate treatment for American tegumentary leishmaniasis results in low lethality, low incidence of relapse, and low late mucosal involvement in a referral centre in Rio de Janeiro, Brazil (2001-2013)
by: Lucia Regina Brahim, et al.

Hypersensitivity eosinophilic myocarditis possibly triggered by meglumine antimoniate
by: Sergio A. Bolivar-Lozano, et al.
Published: (2024-03-01)

FIRST REPORT ON OTOTOXICITY OF MEGLUMINE ANTIMONIATE
by: Cláudia Maria Valete-Rosalino, et al.
Published: (2014-09-01)

Comparison between topical treatment with thioxolone , benzoxonium chloride tincture and intralesional injection of meglumine antymoniate on cutaneous leishmaniasis
by: M.H Daei-Parizi, et al.
Published: (1995-12-01)

Pentoxifylline in the Treatment of Cutaneous Leishmaniasis: A Randomized Clinical Trial in Colombia
by: Maria del Mar Castro, et al.
Published: (2022-03-01)

In vitro and in vivo activity of meglumine antimoniate produced at Farmanguinhos-Fiocruz, Brazil, against Leishmania (Leishmania) amazonensis, L (L.) chagasi and L (Viannia) braziliensis
by: Eliane de Morais-Teixeira, et al.
Published: (2008-06-01)

The Efficacy of Carbon Dioxide Laser in the Treatment of Chronic and Lupoid Cutaneous Leishmaniasis in Kerman City: A Randomized Clinical Trial
by: I Esfandiarpour, et al.
Published: (2014-07-01)

NEPHROTOXICITY ATTRIBUTED TO MEGLUMINE ANTIMONIATE (GLUCANTIME) IN THE TREATMENT OF GENERALIZED CUTANEOUS LEISHMANIASIS
by: M.L.O. RODRIGUES, et al.
Published: (1999-01-01)

The Efficacy, Relapse and Failure in the Treatment of Anthroponotic Cutaneous Leishmaniosis with Intralesional Glucantime Along with Cryotherapy
by: Mehran Karvar, et al.
Published: (2016-03-01)

FACTORS ASSOCIATED TO ADHERENCE TO DIFFERENT TREATMENT SCHEMES WITH MEGLUMINE ANTIMONIATE IN A CLINICAL TRIAL FOR CUTANEOUS LEISHMANIASIS
by: Madelon Novato Ribeiro, et al.
Published: (2014-07-01)

Efficacy of the treatment using a microemulsion loaded with epoxy-α-lapachone in combination with meglumine antimoniate against murine infection by Leishmania (Leishmania) amazonensis
by: Juliana Figueiredo Peixoto, et al.
Published: (2024-04-01)

A Promising Cutaneous Leishmaniasis Treatment with a Nanoemulsion-Based Cream with a Generic Pentavalent Antimony (Ulamina) as the Active Ingredient
by: Johnny Bullón, et al.
Published: (2021-12-01)

High and low doses of antimony (Sb v) in American cutaneous leishmaniasis: a five years follow-up study of 15 patients
by: MP Oliveira-Neto, et al.
Published: (1996-04-01)

Pentavalent Antimony Associated with G-CSF in the Treatment of Cutaneous Leishmaniasis Caused by <i>Leishmania (Viannia) braziliensis</i>
by: Carvel Suprien, et al.
Published: (2024-04-01)

High frequency of skin reactions in patients with leishmaniasis treated with meglumine antimoniate contaminated with heavy metals: a comparative approach using historical controls
by: Gustavo Adolfo Sierra Romero, et al.
Published: (2003-01-01)

Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol
by: Laura Manna, et al.
Published: (2015-05-01)

Preparation and Evaluation of Clinical Effects of Glucantime Gel Mask
by: Sayed Abolfazl Mostafavi, et al.
Published: (2013-06-01)

<i>In Vivo</i> Evaluation of Sepigel-Based Meglumine Antimoniate and Amphotericin B for Cutaneous Leishmaniasis Treatment
by: Atteneri López-Arencibia, et al.
Published: (2024-08-01)

Effects of Meglumine Antimoniate Treatment on Cytokine Production in a Patient with Mucosal Leishmaniasis and Chagas Diseases Co-Infection
by: Karine Rezende-Oliveira, et al.
Published: (2020-05-01)

Biodistribution of meglumine antimoniate in healthy and Leishmania (Leishmania) infantum chagasi-infected BALB/c mice
by: Samanta Etel Treiger Borborema, et al.
Published: (2013-08-01)

A study of comparison and evaluation of various intralesional therapies in cutaneous warts
by: Malay Chaudhary, et al.
Published: (2023-01-01)

Comparisso of intralesionally injected Zink sulfate and pentavalent Antimony compound in treatment of acute cutaneous leishmaniasis
by: A.R GHafarinejhad, et al.
Published: (2000-09-01)

In Vitro Reduced Susceptibility to Pentavalent Antimonials of a <i>Leishmania infantum</i> Isolate from a Human Cutaneous Leishmaniasis Case in Central Italy
by: Aurora Diotallevi, et al.
Published: (2021-05-01)

Evaluation of clinical risk factors for systemic antimony treatment failure in patients with acute cutaneous leishmaniasis referred to dermatology clinics of Mashhad University of Medical Sciences, Iran
by: Yalda Nahidi, et al.
Published: (2023-10-01)

Effect of Antimonial Therapy on Levels of (TNF-α and IL-1β) Cytokines in Cutaneous Leishmaniasis Patients in Iraq
by: Hasan Raheem Khudhur, et al.
Published: (2019-12-01)

Critically Appraised Topic on Canine Leishmaniosis: Does Treatment with Antimonials and Allopurinol Have the Same Clinical and Clinicopathological Efficacy as Treatment with Miltefosine and Allopurinol, after One Month of Treatment?
by: Marina García, et al.
Published: (2024-05-01)

Varicella zoster virus reactivation during or immediately following treatment of tegumentary leishmaniasis with antimony compounds
by: Andrea Barbieri Barros, et al.
Published: (2014-07-01)

Therapeutic Potential of Green Synthesized Copper Nanoparticles Alone or Combined with Meglumine Antimoniate (Glucantime<sup>®</sup>) in Cutaneous Leishmaniasis
by: Aishah E. Albalawi, et al.
Published: (2021-03-01)